Colonoscopy Clinical Trials

Clinical trials related to Colonoscopy Procedure

Consortium for Gut-Brain Communication in Parkinson's Disease Master Protocol

Status: Recruiting
Location: See all (7) locations...
Study Type: Observational
SUMMARY

The purpose of this research study is to identify the role that the gut-brain axis, the group of nerves that connect the brain and gut, plays in Parkinson's disease (PD). The National Institute of Diabetes and Digestive and Kidney Diseases is sponsoring this research study. During this study, specific groups of participants, also known as cohorts, will be identified based on the severity of their PD. There will also be a cohort enrolling participants who do not have Parkinson's and a cohort enrolling participants that are at risk for developing PD. Each of these cohorts will be compared to the others to assess the differences in the gut-brain connection. Participants in this study will: * meet with a medical provider * answer questionnaires * give samples of blood, stool, and saliva * have X-rays taken while swallowing different foods (swallowing study) * have X-rays taken to see how long it takes markers to move through their colon (colon transit study) * have a flexible sigmoidoscopy, where a doctor looks inside the lower part of the colon and takes small tissue samples (biopsies) from the mucosa (lining) * have samples taken of their skin * have an anorectal manometry and a balloon expulsion test, where a small tube and balloon are placed in the rectum to measure muscle function. Participation in the study will last up to 24 months (2 years).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 80
Healthy Volunteers: t
View:

• Aged ≥21 years old and ≤80 years old

• Clinical diagnosis of PD as defined by Movement Disorder Society (MDS) PD Criteria

• Adequate visual, hearing, cognitive, and physical ability

• Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures. Because longitudinal participation is important to the scientific goals of the program, a best estimate of interest, commitment, and geographic feasibility for three years will be documented by the enrolling investigator after interview with the potential enrollee

• Aged ≥21 years old and ≤80 years old

• No known or diagnosed neurodegenerative disease

• Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures

• Resides within the same household as person with PD

• Aged ≥21 years old and ≤80 years old

• Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

Locations
United States
California
Stanford University
RECRUITING
Stanford
Illinois
Rush University
RECRUITING
Chicago
University of Chicago
NOT_YET_RECRUITING
Chicago
Massachusetts
Massachusetts General Hospital
NOT_YET_RECRUITING
Boston
Minnesota
Mayo Clinic
RECRUITING
Rochester
New York
Columbia University
NOT_YET_RECRUITING
New York
South Carolina
Medical University of South Carolina
NOT_YET_RECRUITING
Charleston
Time Frame
Start Date: 2026-07-03
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 250
Treatments
Household Controls
Age-similar household controls. Household control design where controls are matched to people with PD when available.
People with Parkinson's disease
The Parkinson's Disease (PD) cohort will be further classified as mild, moderate, or severe PD as classified by Hoehn and Yahr scale.
Prodromal Parkinson's disease
People with Parkinson's Disease prodromal features. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.
Sponsors
Collaborators: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Medical University of South Carolina, Columbia University, Stanford University, Massachusetts General Hospital, University of Chicago, Rush University Medical Center
Leads: Duke University

This content was sourced from clinicaltrials.gov